Boehringer Ingelheim Pharmaceuticals, Inc.
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Actelion (2017)
Merial (2016) |
| gptkbp:CEO |
gptkb:Hubertus_von_Baumbach
|
| gptkbp:employees |
approximately 50,000
|
| gptkbp:founded |
1885
|
| gptkbp:founder |
gptkb:Albert_Boehringer
|
| gptkbp:global_presence |
over 150 countries
|
| gptkbp:headquarters |
Ingelheim_am_Rhein,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:parent_company |
gptkb:Boehringer_Ingelheim
|
| gptkbp:partnerships |
gptkb:Pfizer
gptkb:Eli_Lilly_and_Company Sanofi |
| gptkbp:products |
prescription medications
|
| gptkbp:research_areas |
diabetes
neurology oncology cardiovascular diseases immunology respiratory diseases |
| gptkbp:research_focus |
animal health
human pharmaceuticals |
| gptkbp:revenue |
approximately €19 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Boehringer_Ingelheim_GmbH
gptkb:Boehringer_Ingelheim_Vetmedica,_Inc. |
| gptkbp:website |
www.boehringer-ingelheim.com
|